JP2014507142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507142A5 JP2014507142A5 JP2013553482A JP2013553482A JP2014507142A5 JP 2014507142 A5 JP2014507142 A5 JP 2014507142A5 JP 2013553482 A JP2013553482 A JP 2013553482A JP 2013553482 A JP2013553482 A JP 2013553482A JP 2014507142 A5 JP2014507142 A5 JP 2014507142A5
- Authority
- JP
- Japan
- Prior art keywords
- oligopeptide
- amino acid
- acid sequence
- composition
- kcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010038807 Oligopeptides Proteins 0.000 claims 33
- 102000015636 Oligopeptides Human genes 0.000 claims 33
- 150000001413 amino acids Chemical group 0.000 claims 29
- 238000000034 method Methods 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 230000002163 immunogen Effects 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 230000001580 bacterial effect Effects 0.000 claims 8
- 150000001720 carbohydrates Chemical class 0.000 claims 8
- 235000014633 carbohydrates Nutrition 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000004676 glycans Chemical class 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 241000295644 Staphylococcaceae Species 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000005875 antibody response Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102000028861 calmodulin binding Human genes 0.000 claims 2
- 108091000084 calmodulin binding Proteins 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 231100000617 superantigen Toxicity 0.000 claims 2
- -1 superantigens Proteins 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108050001427 Avidin/streptavidin Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 101710179002 Hemolytic toxin Proteins 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 241001195348 Nusa Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108010090623 galactose binding protein Proteins 0.000 claims 1
- 102000021529 galactose binding proteins Human genes 0.000 claims 1
- 150000002333 glycines Chemical class 0.000 claims 1
- 230000005745 host immune response Effects 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 101150066555 lacZ gene Proteins 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 101150044170 trpE gene Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440757P | 2011-02-08 | 2011-02-08 | |
| US61/440,757 | 2011-02-08 | ||
| US201161554750P | 2011-11-02 | 2011-11-02 | |
| US61/554,750 | 2011-11-02 | ||
| PCT/US2012/024031 WO2012109167A1 (en) | 2011-02-08 | 2012-02-06 | Immunogenic composition comprising alpha-hemolysin oligopeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014507142A JP2014507142A (ja) | 2014-03-27 |
| JP2014507142A5 true JP2014507142A5 (enExample) | 2015-03-19 |
Family
ID=46638917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553482A Pending JP2014507142A (ja) | 2011-02-08 | 2012-02-06 | α溶血素オリゴペプチドを含む免疫原性組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9109036B2 (enExample) |
| EP (1) | EP2672989A4 (enExample) |
| JP (1) | JP2014507142A (enExample) |
| AU (1) | AU2012214677B2 (enExample) |
| CA (1) | CA2825770A1 (enExample) |
| WO (1) | WO2012109167A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| ES2677723T3 (es) * | 2012-12-28 | 2018-08-06 | Cellestis Limited | Un ensayo de la respuesta inmunológica mediada por células |
| CA2916231C (en) * | 2013-06-19 | 2024-02-06 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| EP3094348B1 (en) | 2014-01-14 | 2025-03-05 | AbVacc, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| US10080790B2 (en) | 2014-09-19 | 2018-09-25 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
| US20180141981A1 (en) * | 2015-01-06 | 2018-05-24 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising engineered alpha-hemolysin oligopeptides |
| EP3532618A4 (en) * | 2016-10-27 | 2020-05-20 | MedImmune, LLC | SIGNAL POLYPEPTIDES FOR IMPROVED PROTEIN SECRETION |
| MX2020001046A (es) | 2017-07-27 | 2020-08-06 | Integrated Biotherapeutic Vaccines Inc | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. |
| IT202000025423A1 (it) | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| CA3204730A1 (en) * | 2021-01-15 | 2022-07-21 | Gowrishankar MUTHUKRISHNAN | Staphylococcus aureus antigen-based nucleic acid vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1499035A (en) | 1975-04-10 | 1978-01-25 | Ts Nii Gematologii I Perelivan | Antistaphylococcus human immune globulin and method of preparing same |
| US4327082A (en) | 1979-07-12 | 1982-04-27 | Adcock-Ingram Laboratories Limited | Mastitis vaccination |
| WO2007143451A2 (en) * | 2006-05-30 | 2007-12-13 | Terman David S | Targeted delivery of oncolytic viruses, anti-tumor proteins, plasmids, toxins, hemolysins & chemotherapy |
| ES2730275T3 (es) * | 2004-09-22 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Composición inmunógena para uso en vacunación contra estafilococos |
| JP2009539979A (ja) | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| EP2419129A2 (en) * | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
| PT2493498T (pt) | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
| SG11201400210RA (en) * | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
| US20150044251A1 (en) * | 2011-12-23 | 2015-02-12 | Novartis Ag | Stable compositions for immunising against staphylococcus aureus |
-
2012
- 2012-02-06 AU AU2012214677A patent/AU2012214677B2/en active Active
- 2012-02-06 US US13/984,226 patent/US9109036B2/en active Active
- 2012-02-06 CA CA2825770A patent/CA2825770A1/en not_active Abandoned
- 2012-02-06 WO PCT/US2012/024031 patent/WO2012109167A1/en not_active Ceased
- 2012-02-06 JP JP2013553482A patent/JP2014507142A/ja active Pending
- 2012-02-06 EP EP12744843.9A patent/EP2672989A4/en not_active Withdrawn
-
2015
- 2015-08-05 US US14/818,817 patent/US20160039888A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Confer et al. | Mannheimia haemolytica in bovine respiratory disease: immunogens, potential immunogens, and vaccines | |
| CN102712680B (zh) | 修饰的肺炎链球菌溶血素(ply)多肽 | |
| RU2735101C2 (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2016522259A5 (enExample) | ||
| US9987342B2 (en) | Immunizing composition | |
| CN103068838B (zh) | 基于重组蛋白的抗链球菌感染疫苗 | |
| JP7072921B2 (ja) | Ａ群レンサ球菌ワクチン | |
| KR102922338B1 (ko) | 폐렴구균 융합 단백질 백신 | |
| JP2021514387A (ja) | ブドウ球菌抗原を含む免疫原性組成物 | |
| US20250064910A1 (en) | A maps vaccine targeting salmonella enterica serovars | |
| CA2912496C (en) | Immunogenic composition for use in therapy | |
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| JP2001515723A (ja) | Ａ群連鎖球菌ワクチン | |
| CN103501808A (zh) | 用于针对肺炎链球菌免疫的组合物 | |
| TWI683668B (zh) | 用於免疫作用中有效抗體生産的新穎蛋白質結構 | |
| Chen et al. | Designing, expression and immunological characterization of a chimeric protein of Mycoplasma pneumoniae | |
| JP7410018B2 (ja) | Ａ群レンサ球菌に対する免疫原性ペプチド | |
| TWI638827B (zh) | 交叉保護性重組抗原及含彼之動物疫苗組成物 | |
| JP2022544407A (ja) | 免疫原性組成物 | |
| JP2020537488A5 (enExample) | ||
| US10590178B2 (en) | Chimeric vaccine against fungal infections | |
| TWI635869B (zh) | 生物型佐劑及含彼之動物疫苗組成物 | |
| CN111088269B (zh) | OprJ-N-M融合基因及其融合蛋白、融合蛋白制备方法以及用途 | |
| WO2024259229A2 (en) | Fusion proteins generating protective antibodies and protective th17 responses for pseudomonas aeruginosa | |
| CN121449699A (zh) | 具有免疫原性的肺炎支原体多肽表位和包含其的重组蛋白、以及肺炎支原体疫苗 |